Nuclear Medicine Market

Nuclear Medicine Market / Radiopharmaceuticals Market by Type (Diagnostic (SPECT-Technetium, PET-F-18), Therapeutic (Beta Emitters-Y-90, Alpha Emitters, Brachytherapy), Application (Neurology,Thyroid, Oncology), Procedures, End User - Global Forecast to 2028

Report Code: PH 3590 May, 2023, by marketsandmarkets.com

The global nuclear medicine market in terms of revenue was estimated to be worth $5.5 billion in 2023 and is poised to reach $9.4 billion by 2028, growing at a CAGR of 11.3% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the growing geriatric population, increasing incidence of cancer and the need for nuclear medicine for the early diagnosis of diseases.

However, low hospital budgets, the slow adoption of technologically advanced systems, and uncertain/poor insurance coverage & reimbursement facilities are factors restraining the growth of this market.

Global Nuclear Medicine Market Trends

Nuclear Medicine/Radiopharmaceuticals Market

To know about the assumptions considered for the study, Request for Free Sample Report

Nuclear Medicine/Radiopharmaceuticals Market

Nuclear Medicine Market Dynamics

Driver: Increasing incidence and prevalence of target conditions

The increasing prevalence of cancer and cardiovascular disease is a key reason encouraging market growth. The majority cases can be prevented through quick detection and treatment; nuclear medicine plays a substantial role in these areas. According to American Heart Association 2022, approximately 19.1 million deaths were attributed to CVD globally in 2020. The age-adjusted death rate per 100,000 population was 239.8 and age-adjusted prevalence rate was 7354.1 per 100,000. As nuclear medicine shows a substantial role in disease diagnosis and treatment, the growing prevalence of these diseases is projected to drive the growth of the market during the forecast period.

Restraint: Short half-life of radiopharmaceuticals

The expiry of a radiopharmaceutical primarily varies on the half-life of the radioisotope and the substance of the radionuclide. For example,in SPECT diagnosis, the radioactivity of Tc-99m is decreased after 6 hours, while I-123 and In-111 isotopes should be used within 13 and 67 hours, respectively. The non-utilization of radioisotopes within the given shelf life causes radiation and chemical decomposition, lowering radiochemical purity to an unacceptable form, which may prove lethal during diagnosis and therapy. Additionally, the shorter half-life of radiopharmaceuticals creates a need for in-house radiopharmaceutical production in cyclotrons/generators within hospital premises, further increasing the capital expenditure for hospitals.

Opportunity: Use of radiopharmaceuticals in neurological applications

Nuclear medicine is mainly used to diagnose various neurological disorders like Alzheimer’s disease, Parkinson's disease (PD) as well as CVD and cancers. The increasing disease burden has prompted a number of companies and stakeholders to focus on expanding the overall applications of radiopharmaceuticals. In April 2022, Curium (France) announced that the US Food and Drug Administration (FDA) approved DaTscan (Ioflupane I 123 Injection) to assist in the evaluation of adult patients with suspected Parkinsonian Syndromes.  This shows an opportunity for players to raise their offerings and market shares by catering to the demand for radiopharmaceuticals in neurological applications.

Challenge: Hospital budget cuts and high equipment costs

The COVID-19 pandemic has made destruction globally; the outbreak has interrupted operations of healthcare systems worldwide. As a result, hospitals have ramped up testing efforts in an struggle to save lives and decrease the spread of the virus. The financial challenges caused by COVID-19 forced governments across the world to implement budget cuts.

The rising cost of prescription drugs and a sharp decline in the proposed budget allocations for Health and Human Services in the US have significantly reduced hospital budgets. A study by the American Hospital Association estimates that federal payment cuts to hospitals would amount to USD 218 billion by 2028, forcing hospitals to allocate smaller budgets annually.

Nuclear Medicine Market Ecosystem Map

Nuclear Medicine/Radiopharmaceuticals Market  Ecosystem

By type, the diagnostic nuclear medicine segment is projected to lead the market of the nuclear medicine industry in 2023

By type, the nuclear medicine market is divided into diagnostic and therapeutic nuclear medicine. The diagnostic nuclear medicine segment is further divided as SPECT and PET radiopharmaceuticals, while the therapeutic radiopharmaceuticals is divided into beta emitters, alpha emitters and brachytherapy isotopes. The diagnostic segment is projected to lead the global market in 2023 due to the increasing use of SPECT and PET imaging, and advances in radiotracers.

The hospitals segment of nuclear medicine industry, is projected to grow at a highest CAGR during the forecast period, by end user

By end user, the nuclear medicine market is divided into hospitals, imaging centers, academic & research centers and other end users, which comprise pharma/biotech companies and contract research organizations. In 2022, the hospital segment dominated the market, due to growing number of diagnostic imaging procedures performed in hospitals and increasing demand for early disease diagnosis.

North America region of nuclear medicine industry, to witness significant growth from 2023 to 2028

On the basis of region, the nuclear medicine market is divided into North America, Europe, Asia Pacific, and Rest of the World. In 2023, North America projected to lead market share of the market. This can be attributed to the advancement of novel technologies for radioisotope production, government funding, growing R&D expenditure and increasing company initiatives in the region.

Nuclear Medicine/Radiopharmaceuticals Market  by Region

To know about the assumptions considered for the study, download the pdf brochure

GE HealthCare (US),Cardinal Health (US), Curium (France),Bayer AG (Germany), Lantheus Holdings, Inc.(US), Bracco Imaging S.p.A. (Italy), PharmaLogic Holdings Corp. (US), Eczacibasi-Monrol Nuclear Products (Turkey), NTP Radioisotopes SOC Ltd (South Africa), Nordion Inc.(Canada), Advanced Accelerator Applications (France), NorthStar Medical Radioisotopes (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Siemens Healthineers (Germany), Jubilant DraxImage,Inc. (Canada).

Scope of the Nuclear Medicine Industry

Report Metric 

Details 

Market Revenue in 2023

$5.5 billion

Projected Revenue by 2028

$9.4 billion

Revenue Rate

Poised to grow at a CAGR of 11.3%

Market Driver

Increasing incidence and prevalence of target conditions

Market Opportunity

Use of radiopharmaceuticals in neurological applications

This study categorizes the global nuclear medicine market to forecast revenue and analyze trends in each of the following submarkets:

By Type

  • Diagnostic Nuclear Medicine
    • SPECT Radiopharmaceuticals
      • Tc-99m
      • I-123
      • Tl-201
      • Ga-67
      • Other SPECT Isotopes
    • PET Radiopharmaceuticals
      • F-18
      • Rb-82
      • Other PET Isotopes
  • Therapeutic Nuclear Medicine
    • Alpha Emitters
      • Ra-223
    • Beta Emitters
      • I-131
      • Y-90
      • Sm-153
      • Lu-177
      • Re-186
      • Other Beta Emitters
  • Brachytherapy Isotopes
      • I-125
      • Ir-192
      • Pd-103
      • Cs-131
      • Other Brachytherapy Isotopes

By Applications

  • Diagnostic Applications
    • SPECT Applications
      • Cardiology
      • Bone Scans
      • Thyroid Applications
      • Pulmonary Scans
      • Other SPECT Applications
    • PET Applications
      • Oncology
      • Cardiology
      • Neurology
      • Other PET Applications
    • Therapeutic Applications
      • Thyroid Indications
      • Bone Metastasis
      • Lymphoma
      • Endocrine Tumors
      • Other Indications

By Procedural Volume Assessment

  • Diagnostic Procedures
    • SPECT Procedures
    • PET Procedures
  • Therapeutic Procedures

By End User

  • Hospitals
  • Imaging Centers
  • Academic & Research Centers
  • Other end users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • Rest of APAC (RoAPAC)
  • RoW

Recent Developments of Nuclear Medicine Industry

  • In January 2023, NorthStar Medical Radioisotopes (US) achieved a major milestone in advancing its new technology for non-uranium-based production of the critical medical radioisotope, molybdenum-99 (Mo-99).
  • In November 2022, Curium (France) announced that the US Food and Drug Administration (FDA) approved DaTscan (Ioflupane I 123 Injection) to assist in evaluating adult patients with suspected Parkinsonian Syndromes.
  • In October 2022, Blue Earth Diagnostics (UK) signed a data-sharing agreement with Siemens Healthineers (Germany) and the University Hospital of the Technical University of Munich (TUM) for 18F-rhPSMA-7.3, an investigational PET imaging agent, to support AI-based algorithms development.
  • In January 2021, Advanced Accelerator Applications (France) signed a multi-year exclusive supply agreement for lutetium-177 with the University of Missouri Research Reactor (MURR). Through this agreement, MURR will supply AAA with GMP-quality lutetium-177 chloride, the precursor for developing Lutathera and other Lu-177-based therapeutics.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 52)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 57)
    2.1 RESEARCH DATA 
    2.2 RESEARCH METHODOLOGY STEPS 
          FIGURE 1 RESEARCH METHODOLOGY: NUCLEAR MEDICINE MARKET
          FIGURE 2 RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Secondary sources
           2.2.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                    2.2.2.1 Primary sources
                    2.2.2.2 Key insights from primary sources
    2.3 MARKET SIZE ESTIMATION 
          FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 6 REVENUE SHARE ANALYSIS: CARDINAL HEALTH
          FIGURE 7 REVENUE ANALYSIS OF TOP FIVE COMPANIES: MARKET (2022)
          FIGURE 8 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MARKET (2023–2028)
          FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
          FIGURE 10 TOP-DOWN APPROACH
    2.4 MARKET DATA ESTIMATION AND TRIANGULATION 
          FIGURE 11 DATA TRIANGULATION METHODOLOGY
    2.5 STUDY ASSUMPTIONS 
    2.6 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT: MARKET
    2.7 STUDY LIMITATIONS 
    2.8 MARKET: RECESSION IMPACT 
 
3 EXECUTIVE SUMMARY (Page No. - 71)
    FIGURE 12 NUCLEAR MEDICINE MARKET SIZE, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 NUCLEAR MEDICINE MARKET SHARE FOR SPECT APPLICATIONS, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 NUCLEAR MEDICINE MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF NUCLEAR MEDICINE MARKET
 
4 PREMIUM INSIGHTS (Page No. - 75)
    4.1 MARKET OVERVIEW 
          FIGURE 17 HIGH PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY TYPE AND COUNTRY (2022) 
          FIGURE 18 US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY TYPE, 2023 VS. 2028
          FIGURE 19 SPECT PROCEDURES TO CONTINUE TO DOMINATE DIAGNOSTIC PROCEDURES MARKET IN 2028
    4.4 NUCLEAR MEDICINE RADIOISOTOPES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 20 CHINA TO WITNESS HIGHEST GROWTH IN MARKET DURING FORECAST PERIOD
    4.5 NUCLEAR MEDICINE EQUIPMENT MARKET, BY APPLICATION 
          FIGURE 21 DIAGNOSTIC APPLICATIONS TO DOMINATE MARKET DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 79)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 22 NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidence and prevalence of target conditions
                    5.2.1.2 Development of alpha-radioimmunotherapy-based targeted cancer treatments
                    5.2.1.3 Initiatives to reduce demand and supply gap of Mo-99
           5.2.2 RESTRAINTS
                    5.2.2.1 Short half-life of radiopharmaceuticals
                                TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Use of radiopharmaceuticals in neurological applications
                    5.2.3.2 Growth opportunities in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Hospital budget cuts and high equipment costs
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 23 VALUE CHAIN ANALYSIS OF MARKET
    5.4 ECOSYSTEM COVERAGE 
    5.5 REGULATORY LANDSCAPE 
           5.5.1 NORTH AMERICA
                    5.5.1.1 US
                    5.5.1.2 Canada
           5.5.2 EUROPEAN UNION
           5.5.3 ASIA PACIFIC
                    5.5.3.1 Australia
                    5.5.3.2 India
                    5.5.3.3 China
           5.5.4 REST OF THE WORLD
                    5.5.4.1 Turkey
                    5.5.4.2 UAE
                    5.5.4.3 South Africa
                                TABLE 3 MARKET: REGULATORY LANDSCAPE
    5.6 PORTER’S FIVE FORCES ANALYSIS 
           5.6.1 PORTER’S FIVE FORCES ANALYSIS: MARKET
           5.6.2 DEGREE OF COMPETITION
           5.6.3 BARGAINING POWER OF SUPPLIERS
           5.6.4 BARGAINING POWER OF BUYERS
           5.6.5 THREAT FROM SUBSTITUTES
           5.6.6 THREAT FROM NEW ENTRANTS
    5.7 PIPELINE ANALYSIS 
          TABLE 4 PIPELINE ANALYSIS
    5.8 PATENT ANALYSIS 
           5.8.1 PATENT PUBLICATION TRENDS FOR MARKET
                    FIGURE 24 PATENT PUBLICATION TRENDS (JANUARY 2015–DECEMBER 2022)
                    FIGURE 25 TOP 9 COMPANIES WITH HIGHEST NUMBER OF PATENT APPLICATIONS IN LAST 10 YEARS
    5.9 INDUSTRY TRENDS 
           5.9.1 INCREASING PARTNERSHIPS & COLLABORATIONS FOR INNOVATION
           5.9.2 GROWING DEMAND FOR PET RADIOPHARMACEUTICALS IN ONCOLOGY AND NEUROLOGY APPLICATIONS
           5.9.3 ADVANCES IN RESEARCH & DEVELOPMENT OF RADIOPHARMACEUTICALS IN EMERGING COUNTRIES
    5.10 PRICING ANALYSIS 
           TABLE 5 AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS, BY TYPE
           TABLE 6 AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS IN EASTERN EUROPE, BY TYPE
           TABLE 7 AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS IN MENAT REGION, BY TYPE
           5.10.1 AVERAGE SELLING PRICE TREND ANALYSIS
    5.11 KEY CONFERENCES & EVENTS IN 2023–2024 
           TABLE 8 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
    5.12 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
                     TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
           5.12.2 BUYING CRITERIA
                     FIGURE 27 KEY BUYING CRITERIA FOR END USERS
                     TABLE 10 KEY BUYING CRITERIA FOR END USERS
 
6 NUCLEAR MEDICINE MARKET, BY TYPE (Page No. - 100)
    6.1 INTRODUCTION 
          TABLE 11 NUCLEAR MEDICINE EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION)
    6.2 DIAGNOSTIC NUCLEAR MEDICINE 
          TABLE 12 NUCLEAR MEDICINE RADIOISOTOPES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 13 NUCLEAR MEDICINE RADIOISOTOPES MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 14 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 15 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 16 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.1 SPECT RADIOPHARMACEUTICALS
                    TABLE 17 ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES DUE TO SEVERE TC-99M SHORTAGES
                    TABLE 18 SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 19 SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 20 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 21 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 22 ASIA PACIFIC: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.2.1.1 Tc-99m
                               6.2.1.1.1 Tc-99m commanded largest share of SPECT radiopharmaceuticals market in 2022
                                              TABLE 23 TC-99M MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 24 NORTH AMERICA: TC-99M MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 25 EUROPE: TC-99M MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 26 ASIA PACIFIC: TC-99M MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.2.1.2 I-123
                               6.2.1.2.1 Reduced exposure to radiation and lower risk of patients developing radiation-induced cancer to drive demand
                                              TABLE 27 I-123 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 28 NORTH AMERICA: I-123 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 29 EUROPE: I-123 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 30 ASIA PACIFIC: I-123 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.2.1.3 Tl-201
                               6.2.1.3.1 Potential substitute to Tc-99m to drive demand for TI-201
                                              TABLE 31 TI-201 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 32 NORTH AMERICA: TI-201 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 33 EUROPE: TI-201 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 34 ASIA PACIFIC: TI-201 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.2.1.4 Ga-67
                               6.2.1.4.1 Long half-life of Ga-67 to facilitate easy sales and distribution
                                              TABLE 35 GA-67 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 36 NORTH AMERICA: GA-67 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 37 EUROPE: GA-67 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 38 ASIA PACIFIC: GA-67 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.2.1.5 Other SPECT isotopes
                                TABLE 39 OTHER SPECT ISOTOPES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 40 NORTH AMERICA: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 41 EUROPE: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 42 ASIA PACIFIC: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.2 PET RADIOPHARMACEUTICALS
                    TABLE 43 PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 44 PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 45 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 46 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 47 ASIA PACIFIC: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.2.2.1 F-18
                               6.2.2.1.1 F-18 to command largest share of PET radiopharmaceuticals market in 2022
                                              TABLE 48 F-18 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 49 NORTH AMERICA: F-18 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 50 EUROPE: F-18 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 51 ASIA PACIFIC: F-18 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.2.2.2 Rb-82
                               6.2.2.2.1 High accuracy offered by Rb-82 isotopes to support market growth
                                              TABLE 52 RB-82 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 53 NORTH AMERICA: RB-82 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 54 EUROPE: RB-82 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 55 ASIA PACIFIC: RB-82 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.2.2.3 Other PET isotopes
                                TABLE 56 OTHER PET ISOTOPES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 57 NORTH AMERICA: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 58 EUROPE: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 59 ASIA PACIFIC: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 THERAPEUTIC NUCLEAR MEDICINE 
          TABLE 60 MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 61 MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 62 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 63 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 64 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.1 ALPHA EMITTERS
                    6.3.1.1 Ra-223
                               6.3.1.1.1 Easy production of Ra-223 to favor market growth
                                              TABLE 65 RA-223 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 66 NORTH AMERICA: RA-223 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 67 EUROPE: RA-223 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 68 ASIA PACIFIC: RA-223 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.2 BETA EMITTERS
                    TABLE 69 BETA EMITTERS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 70 BETA EMITTERS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 71 NORTH AMERICA: BETA EMITTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 72 EUROPE: BETA EMITTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 73 ASIA PACIFIC: BETA EMITTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.2.1 I-131
                               6.3.2.1.1 I-131 to account for largest share of beta emitters market during forecast period
                                              TABLE 74 I-131 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 75 NORTH AMERICA: I-131 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 76 EUROPE: I-131 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 77 ASIA PACIFIC: I-131 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.2.2 Y-90
                               6.3.2.2.1 Increasing applications in treating hepatocellular carcinoma to propel growth
                                              TABLE 78 Y-90 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 79 NORTH AMERICA: Y-90 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 80 EUROPE: Y-90 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 81 ASIA PACIFIC: Y-90 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.2.3 Sm-153
                               6.3.2.3.1 Increasing incidence of bone metastasis to drive market
                                              TABLE 82 SM-153 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 83 NORTH AMERICA: SM-153 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 84 EUROPE: SM-153 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 85 ASIA PACIFIC: SM-153 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.2.4 Lu-177
                               6.3.2.4.1 Increasing incidence of neuroendocrine cancer to boost demand
                                              TABLE 86 LU-177 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 87 NORTH AMERICA: LU-177 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 88 EUROPE: LU-177 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 89 ASIA PACIFIC: LU-177 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.2.5 Re-186
                               6.3.2.5.1 Wide usage of Re-186 for bone pain relief to fuel growth
                                              TABLE 90 RE-186 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 91 NORTH AMERICA: RE-186 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 92 EUROPE: RE-186 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 93 ASIA PACIFIC: RE-186 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.2.6 Other beta emitters
                                TABLE 94 OTHER BETA EMITTERS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 95 NORTH AMERICA: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 96 EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 97 ASIA PACIFIC: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.3 BRACHYTHERAPY ISOTOPES
                    TABLE 98 BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 99 BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 100 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 101 EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 102 ASIA PACIFIC: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.3.1 I-125
                               6.3.3.1.1 I-125 to account for largest share of brachytherapy isotopes market
                                              TABLE 103 I-125 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 104 NORTH AMERICA: I-125 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 105 EUROPE: I-125 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 106 ASIA PACIFIC: I-125 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.3.2 Ir-192
                               6.3.3.2.1 Growing use of Ir-192 to treat prostate, skin, and oral cancer to boost growth
                                              TABLE 107 IR-192 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 108 NORTH AMERICA: IR-192 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 109 EUROPE: IR-192 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 110 ASIA PACIFIC: IR-192 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.3.3 Pd-103
                               6.3.3.3.1 Extensive use of Pd-103 in treatment of aggressive tumors to propel growth
                                              TABLE 111 PD-103 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 112 NORTH AMERICA: PD-103 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 113 EUROPE: PD-103 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 114 ASIA PACIFIC: PD-103 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.3.4 Cs-131
                               6.3.3.4.1 Growing use of Cs-131 in gynecological applications to aid growth
                                              TABLE 115 CS-131 MARKET, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 116 NORTH AMERICA: CS-131 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 117 EUROPE: CS-131 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 118 ASIA PACIFIC: CS-131 MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    6.3.3.5 Other brachytherapy isotopes
                                TABLE 119 OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 120 NORTH AMERICA: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 121 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 122 ASIA PACIFIC: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 NUCLEAR MEDICINE MARKET, BY APPLICATION (Page No. - 149)
    7.1 INTRODUCTION 
          TABLE 123 NUCLEAR MEDICINE EQUIPMENT MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    7.2 DIAGNOSTIC APPLICATIONS 
          TABLE 124 MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 125 MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 126 NORTH AMERICA: MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 127 EUROPE: MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 128 ASIA PACIFIC: MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
           7.2.1 SPECT APPLICATIONS
                    TABLE 129 MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 130 MARKET FOR SPECT APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 131 NORTH AMERICA: MARKET FOR SPECT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 132 EUROPE: MARKET FOR SPECT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 133 ASIA PACIFIC: MARKET FOR SPECT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    7.2.1.1 Cardiology
                               7.2.1.1.1 Rising incidence of CVDs to increase demand for cardiac diagnostic scans
                                              TABLE 134 MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 135 NORTH AMERICA: MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 136 EUROPE: MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 137 ASIA PACIFIC: MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    7.2.1.2 Bone scans
                               7.2.1.2.1 High precision of SPECT to boost adoption of bone scans
                                              TABLE 138 MARKET FOR SPECT BONE SCAN APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 139 NORTH AMERICA: MARKET FOR SPECT BONE SCAN APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 140 EUROPE: MARKET FOR SPECT BONE SCAN APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 141 ASIA PACIFIC: MARKET FOR SPECT BONE SCAN APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    7.2.1.3 Thyroid
                               7.2.1.3.1 Rising demand for combination SPECT/CT therapy to drive market growth
                                              TABLE 142 NUCLEAR MEDICINE RADIOISOTOPES MARKET FOR SPECT THYROID APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 143 NORTH AMERICA: MARKET FOR SPECT THYROID APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 144 EUROPE: MARKET FOR SPECT THYROID APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 145 ASIA PACIFIC: MARKET FOR SPECT THYROID APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    7.2.1.4 Pulmonary scans
                               7.2.1.4.1 High accuracy and sensitivity of SPECT/CT pulmonary imaging to boost market
                                              TABLE 146 MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 147 NORTH AMERICA: MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 148 EUROPE: MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 149 ASIA PACIFIC: MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    7.2.1.5 Other SPECT applications
                                TABLE 150 MARKET FOR OTHER SPECT APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 151 NORTH AMERICA: MARKET FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 152 EUROPE: MARKET FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 153 ASIA PACIFIC: MARKET FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
           7.2.2 PET APPLICATIONS
                    TABLE 154 NUCLEAR MEDICINE MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 155 MARKET FOR PET APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 156 NORTH AMERICA: MARKET FOR PET APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 157 EUROPE: MARKET FOR PET APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 158 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    7.2.2.1 Oncology
                               7.2.2.1.1 Increasing incidence of cancer to fuel market growth
                                              TABLE 159 MARKET FOR PET ONCOLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 160 NORTH AMERICA: MARKET FOR PET ONCOLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 161 EUROPE: MARKET FOR PET ONCOLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 162 ASIA PACIFIC: MARKET FOR PET ONCOLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    7.2.2.2 Cardiology
                               7.2.2.2.1 Growing preference for FDG in cardiac imaging to propel market
                                              TABLE 163 MARKET FOR PET CARDIOLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 164 NORTH AMERICA: MARKET FOR PET CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 165 EUROPE: MARKET FOR PET CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 166 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    7.2.2.3 Neurology
                               7.2.2.3.1 Increasing incidence of AD, epilepsy, and Parkinson’s disease to increase adoption of PET imaging
                                              TABLE 167 NUCLEAR MEDICINE EQUIPMENT MARKET FOR PET NEUROLOGY APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                              TABLE 168 NORTH AMERICA: MARKET FOR PET NEUROLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 169 EUROPE: MARKET FOR PET NEUROLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                              TABLE 170 ASIA PACIFIC: MARKET FOR PET NEUROLOGY APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    7.2.2.4 Other PET applications
                                TABLE 171 MARKET FOR OTHER PET APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 172 NORTH AMERICA: MARKET FOR OTHER PET APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 173 EUROPE: MARKET FOR OTHER PET APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 174 ASIA PACIFIC: NUCLEAR MEDICINE MARKET SHARE FOR OTHER PET APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 THERAPEUTIC APPLICATIONS 
          TABLE 175 MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 176 MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 177 NORTH AMERICA: MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 178 EUROPE: MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 179 ASIA PACIFIC: MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
           7.3.1 THYROID INDICATIONS
                    7.3.1.1 Increasing prevalence of thyroid disorders to boost market
                                TABLE 180 MARKET FOR THYROID INDICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 181 NORTH AMERICA: MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 182 EUROPE: MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 183 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
           7.3.2 BONE METASTASIS
                    7.3.2.1 Introduction of novel therapies for bone metastasis to positively impact market growth
                                TABLE 184 NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 185 NORTH AMERICA: MARKET FOR BONE METASTASIS APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 186 EUROPE: MARKET FOR BONE METASTASIS APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 187 ASIA PACIFIC: MARKET FOR BONE METASTASIS APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
           7.3.3 ENDOCRINE TUMORS
                    7.3.3.1 US to dominate therapeutic market for endocrine tumor applications
                                TABLE 188 NUCLEAR MEDICINE RADIOISOTOPES MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 189 NORTH AMERICA: MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 190 EUROPE: MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 191 ASIA PACIFIC: MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
           7.3.4 LYMPHOMA
                    7.3.4.1 Development of new isotopes for treatment of lymphoma to present huge growth opportunities
                                TABLE 192 MARKET FOR LYMPHOMA APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 193 NORTH AMERICA: MARKET FOR LYMPHOMA APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 194 EUROPE: MARKET FOR LYMPHOMA APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 195 ASIA PACIFIC: NUCLEAR MEDICINE MARKET SIZE FOR LYMPHOMA APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
           7.3.5 OTHER THERAPEUTIC APPLICATIONS
                    TABLE 196 MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 197 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 198 EUROPE: MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 199 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 NUCLEAR MEDICINE MARKET: PROCEDURAL VOLUME ASSESSMENT (Page No. - 182)
    8.1 INTRODUCTION 
          TABLE 200 NUCLEAR MEDICINE EQUIPMENT MARKET, BY PROCEDURE, 2021–2028 (THOUSAND PROCEDURES)
          TABLE 201 NUCLEAR MEDICINE RADIOISOTOPES MARKET, BY REGION, 2021–2028 (THOUSAND PROCEDURES)
    8.2 DIAGNOSTIC PROCEDURES 
           8.2.1 HIGH PREVALENCE OF CANCER AND CARDIAC DISEASES TO DRIVE MARKET GROWTH
                    TABLE 202 MARKET FOR DIAGNOSTIC PROCEDURES, BY TYPE, 2021–2028 (THOUSAND PROCEDURES)
                    TABLE 203 MARKET FOR DIAGNOSTIC PROCEDURES, BY REGION, 2021–2028 (THOUSAND PROCEDURES)
    8.3 THERAPEUTIC PROCEDURES 
           8.3.1 GROWING DEMAND FOR NON-INVASIVE METHODS TO SUPPORT MARKET GROWTH
                    TABLE 204 NUCLEAR MEDICINE MARKET SHARE FOR THERAPEUTIC PROCEDURES, BY TYPE, 2021–2028 (THOUSAND PROCEDURES)
                    TABLE 205 MARKET FOR THERAPEUTIC PROCEDURES, BY REGION, 2021–2028 (THOUSAND PROCEDURES)
 
9 NUCLEAR MEDICINE MARKET, BY END USER (Page No. - 186)
    9.1 INTRODUCTION 
          TABLE 206 NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.2 HOSPITALS 
           9.2.1 RISING TREND OF MODERNIZING IMAGING WORKFLOW TO DRIVE ADOPTION OF IMAGING SYSTEMS IN HOSPITALS
                    TABLE 207 NUCLEAR MEDICINE RADIOISOTOPES MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 208 NORTH AMERICA: MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 209 EUROPE: MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 210 ASIA PACIFIC: MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 IMAGING CENTERS 
           9.3.1 GROWING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH
                    TABLE 211 NUCLEAR MEDICINE MARKET FOR IMAGING CENTERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 212 NORTH AMERICA: MARKET FOR IMAGING CENTERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 213 EUROPE: MARKET FOR IMAGING CENTERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 214 ASIA PACIFIC: MARKET FOR IMAGING CENTERS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 ACADEMIC & RESEARCH CENTERS 
           9.4.1 INCREASING COLLABORATIONS BETWEEN NUCLEAR IMAGING COMPANIES AND ACADEMIA TO PROPEL MARKET GROWTH
                    TABLE 215 MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 216 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 217 EUROPE: MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 218 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.5 OTHER END USERS 
          TABLE 219 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 220 NORTH AMERICA: NUCLEAR MEDICINE MARKET SIZE FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 221 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 222 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 NUCLEAR MEDICINE MARKET, BY REGION (Page No. - 196)
     10.1 INTRODUCTION 
             TABLE 223 NUCLEAR MEDICINE EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             10.2.1 NORTH AMERICA: IMPACT OF ECONOMIC RECESSION
                      FIGURE 28 NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT
                        TABLE 224 NORTH AMERICA: NUCLEAR MEDICINE MARKET REPORT, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 225 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 226 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 227 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 228 NORTH AMERICA: MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 229 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 230 NORTH AMERICA: MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 231 NORTH AMERICA: MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 232 NORTH AMERICA: NUCLEAR MEDICINE MARKET SHARE, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 233 NORTH AMERICA: MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 234 NORTH AMERICA: MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 235 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 236 NORTH AMERICA: MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 237 NORTH AMERICA: NUCLEAR MEDICINE EQUIPMENT MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 US
                        10.2.2.1 US to dominate North American nuclear medicine market during forecast period
                                      TABLE 238 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 239 US: NUCLEAR MEDICINE MARKET TRENDS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 240 US: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 241 US: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 242 US: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 243 US: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 244 US: MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 245 US: MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 246 US: NUCLEAR MEDICINE MARKET REPORT, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 247 US: NUCLEAR MEDICINE MARKET SHARE FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 248 US: MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 249 US: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 250 US: NUCLEAR MEDICINE RADIOISOTOPES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 251 US: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Increasing initiatives for medical isotope development to support market growth
                                      TABLE 252 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 253 CANADA: NUCLEAR MEDICINE MARKET TRENDS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 254 CANADA: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 255 CANADA: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 256 CANADA: MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 257 CANADA: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 258 CANADA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 259 CANADA: MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 260 CANADA: NUCLEAR MEDICINE MARKET REPORT, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 261 CANADA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 262 CANADA: MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 263 CANADA: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 264 CANADA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 265 CANADA: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             10.3.1 EUROPE: IMPACT OF ECONOMIC RECESSION
                        TABLE 266 EUROPE: NUCLEAR MEDICINE MARKET TRENDS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 267 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 268 EUROPE: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 269 EUROPE: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 270 EUROPE: MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 271 EUROPE: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 272 EUROPE: MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 273 EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 274 EUROPE: NUCLEAR MEDICINE MARKET REPORT, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 275 EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 276 EUROPE: MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 277 EUROPE: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 278 EUROPE: NUCLEAR MEDICINE RADIOISOTOPES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 279 EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Well-established healthcare system to drive market growth
                                      TABLE 280 GERMANY: NUCLEAR MEDICINE MARKET TRENDS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 281 GERMANY: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 282 GERMANY: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 283 GERMANY: MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 284 GERMANY: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 285 GERMANY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 286 GERMANY: NUCLEAR MEDICINE MARKET REPORT FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 287 GERMANY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 288 GERMANY: MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 289 GERMANY: MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 290 GERMANY: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 291 GERMANY: NUCLEAR MEDICINE EQUIPMENT MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 292 GERMANY: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Rising incidence of diseases such as cancer, Alzheimer’s, and Parkinson’s disease to favor market growth
                                      TABLE 293 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 294 FRANCE: NUCLEAR MEDICINE MARKET TRENDS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 295 FRANCE: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 296 FRANCE: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 297 FRANCE: NUCLEAR MEDICINE MARKET DEMAND FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 298 FRANCE: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 299 FRANCE: MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 300 FRANCE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 301 FRANCE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 302 FRANCE: MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 303 FRANCE: MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 304 FRANCE: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 305 FRANCE: NUCLEAR MEDICINE RADIOISOTOPES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 306 FRANCE: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 UK
                        10.3.4.1 Growing demand for diagnostic imaging and growing awareness to drive market growth
                                      TABLE 307 UK: NUCLEAR MEDICINE MARKET OVERVIEW, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 308 UK: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 309 UK: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 310 UK: NUCLEAR MEDICINE MARKET DEMAND FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 311 UK: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 312 UK: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 313 UK: MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 314 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 315 UK: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 316 UK: MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 317 UK: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 318 UK: NUCLEAR MEDICINE EQUIPMENT MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 319 UK: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Rising geriatric population to support market growth
                                      TABLE 320 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 321 ITALY: NUCLEAR MEDICINE MARKET OVERVIEW, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 322 ITALY: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 323 ITALY: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 324 ITALY: NUCLEAR MEDICINE MARKET DEMAND FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 325 ITALY: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 326 ITALY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 327 ITALY: MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 328 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 329 ITALY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 330 ITALY: MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 331 ITALY: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 332 ITALY: NUCLEAR MEDICINE RADIOISOTOPES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 333 ITALY: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Increasing initiatives by SEMNIM to drive growth
                                      TABLE 334 SPAIN: NUCLEAR MEDICINE MARKET OVERVIEW, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 335 SPAIN: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 336 SPAIN: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 337 SPAIN: NUCLEAR MEDICINE MARKET DEMAND FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 338 SPAIN: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 339 SPAIN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 340 SPAIN: MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 341 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 342 SPAIN: MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 343 SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 344 SPAIN: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 345 SPAIN: NUCLEAR MEDICINE EQUIPMENT MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 346 SPAIN: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 347 REST OF EUROPE: NUCLEAR MEDICINE MARKET OVERVIEW, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 348 REST OF EUROPE: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 349 REST OF EUROPE: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 350 REST OF EUROPE: NUCLEAR MEDICINE MARKET DEMAND FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 351 REST OF EUROPE: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 352 REST OF EUROPE: MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 353 REST OF EUROPE: MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 354 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 355 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 356 REST OF EUROPE: MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 357 REST OF EUROPE: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 358 REST OF EUROPE: NUCLEAR MEDICINE RADIOISOTOPES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 359 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             10.4.1 ASIA PACIFIC: IMPACT OF ECONOMIC RECESSION
                        FIGURE 29 ASIA PACIFIC: NUCLEAR MEDICINE MARKET SNAPSHOT (2022)
                        TABLE 360 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 361 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 362 ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 363 ASIA PACIFIC: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 364 ASIA PACIFIC: NUCLEAR MEDICINE MARKET REPORT FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 365 ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 366 ASIA PACIFIC: MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 367 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 368 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 369 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 370 ASIA PACIFIC: MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 371 ASIA PACIFIC: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 372 ASIA PACIFIC: NUCLEAR MEDICINE EQUIPMENT MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 373 ASIA PACIFIC: NUCLEAR MEDICINE MARKET OVERVIEW, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Japan to dominate APAC nuclear medicine market
                                      TABLE 374 JAPAN: NUCLEAR MEDICINE MARKET GROWTH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 375 JAPAN: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 376 JAPAN: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 377 JAPAN: MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 378 JAPAN: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 379 JAPAN: MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 380 JAPAN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 381 JAPAN: NUCLEAR MEDICINE MARKET REPORT, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 382 JAPAN: MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 383 JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 384 JAPAN: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 385 JAPAN: NUCLEAR MEDICINE RADIOISOTOPES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 386 JAPAN: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 CHINA
                        10.4.3.1 Increasing nuclear medicine infrastructure and growing prevalence of chronic diseases to augment market
                                      TABLE 387 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 388 CHINA: NUCLEAR MEDICINE MARKET GROWTH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 389 CHINA: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 390 CHINA: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 391 CHINA: MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 392 CHINA: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 393 CHINA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 394 CHINA: MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 395 CHINA: NUCLEAR MEDICINE MARKET REPORT, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 396 CHINA: MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 397 CHINA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 398 CHINA: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 399 CHINA: NUCLEAR MEDICINE EQUIPMENT MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 400 CHINA: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
                        TABLE 401 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET GROWTH, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 402 REST OF ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 403 REST OF ASIA PACIFIC: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 404 REST OF ASIA PACIFIC: MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 405 REST OF ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 406 REST OF ASIA PACIFIC: MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 407 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 408 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET REPORT, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 409 REST OF ASIA PACIFIC: MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 410 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 411 REST OF ASIA PACIFIC: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 412 REST OF ASIA PACIFIC: NUCLEAR MEDICINE RADIOISOTOPES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 413 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.5 REST OF THE WORLD 
             10.5.1 REST OF THE WORLD: IMPACT OF ECONOMIC RECESSION
                        TABLE 414 REST OF THE WORLD: NUCLEAR MEDICINE MARKET GROWTH, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 415 REST OF THE WORLD: DIAGNOSTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 416 REST OF THE WORLD: MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 417 REST OF THE WORLD: MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 418 REST OF THE WORLD: THERAPEUTIC NUCLEAR MEDICINES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 419 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 420 REST OF THE WORLD: MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 421 REST OF THE WORLD: NUCLEAR MEDICINE MARKET REPORT, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 422 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 423 REST OF THE WORLD: MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 424 REST OF THE WORLD: MARKET FOR PET APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 425 REST OF THE WORLD: NUCLEAR MEDICINE EQUIPMENT MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 426 REST OF THE WORLD: NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 279)
     11.1 INTRODUCTION 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 427 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 MARKET RANKING ANALYSIS 
             FIGURE 30 NUCLEAR MEDICINE MARKET GROWTH: MARKET RANKING, 2022
     11.4 REVENUE ANALYSIS OF KEY MARKET PLAYERS 
             FIGURE 31 REVENUE SHARE ANALYSIS OF KEY PLAYERS
     11.5 COMPANY EVALUATION MATRIX 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 32 NUCLEAR MEDICINE EQUIPMENT MARKET: COMPANY EVALUATION MATRIX (2021)
     11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 33 NUCLEAR MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES
     11.7 COMPETITIVE BENCHMARKING 
             11.7.1 OVERALL FOOTPRINT OF KEY PLAYERS
                        TABLE 428 OVERALL FOOTPRINT OF KEY PLAYERS
                        TABLE 429 REGIONAL FOOTPRINT OF KEY PLAYERS
                        TABLE 430 TYPE FOOTPRINT OF KEY PLAYERS
     11.8 COMPETITIVE SCENARIO 
             11.8.1 PRODUCT APPROVALS & ENHANCEMENTS
                        TABLE 431 KEY PRODUCT APPROVALS & ENHANCEMENTS
             11.8.2 DEALS
                        TABLE 432 KEY DEALS
             11.8.3 OTHER DEVELOPMENTS
                        TABLE 433 KEY OTHER DEVELOPMENTS
 
12 COMPANY PROFILES (Page No. - 294)
     12.1 MAJOR PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 GE HEALTHCARE
                        TABLE 434 GE HEALTHCARE: BUSINESS OVERVIEW
                        FIGURE 34 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
             12.1.2 CARDINAL HEALTH
                        TABLE 435 CARDINAL HEALTH: BUSINESS OVERVIEW
                        FIGURE 35 CARDINAL HEALTH: COMPANY SNAPSHOT (2022)
             12.1.3 CURIUM
                        TABLE 436 CURIUM: BUSINESS OVERVIEW
             12.1.4 BAYER AG
                        TABLE 437 BAYER AG: BUSINESS OVERVIEW
                        FIGURE 36 BAYER AG: COMPANY SNAPSHOT (2021)
             12.1.5 LANTHEUS HOLDINGS, INC.
                        TABLE 438 LANTHEUS HOLDINGS, INC.: BUSINESS OVERVIEW
                        FIGURE 37 LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT (2021)
             12.1.6 BRACCO IMAGING S.P.A.
                        TABLE 439 BRACCO IMAGING S.P.A.: BUSINESS OVERVIEW
             12.1.7 PHARMALOGIC HOLDINGS CORP.
                        TABLE 440 PHARMALOGIC HOLDINGS CORP.: BUSINESS OVERVIEW
             12.1.8 ECZACIBASI-MONROL NUCLEAR PRODUCTS
                        TABLE 441 ECZACIBASI-MONROL NUCLEAR PRODUCTS: BUSINESS OVERVIEW
             12.1.9 NTP RADIOISOTOPES SOC LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION)
                        TABLE 442 NTP RADIOISOTOPES SOC LTD.: BUSINESS OVERVIEW
             12.1.10 NORDION INC.
                        TABLE 443 NORDION INC.: BUSINESS OVERVIEW
             12.1.11 ADVANCED ACCELERATOR APPLICATIONS (A NOVARTIS COMPANY)
                        TABLE 444 ADVANCED ACCELERATOR APPLICATIONS: BUSINESS OVERVIEW
             12.1.12 NORTHSTAR MEDICAL RADIOISOTOPES
                        TABLE 445 NORTHSTAR MEDICAL RADIOISOTOPES: BUSINESS OVERVIEW
             12.1.13 ECKERT & ZIEGLER
                        TABLE 446 ECKERT & ZIEGLER: BUSINESS OVERVIEW
                        FIGURE 38 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2021)
             12.1.14 ISOTOPE JSC
                        TABLE 447 JOINT STOCK COMPANY ISOTOPE (ISOTOPE JSC): BUSINESS OVERVIEW
             12.1.15 SIEMENS HEALTHINEERS
                        TABLE 448 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
                        FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2022)
             12.1.16 JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA)
                        TABLE 449 JUBILANT DRAXIMAGE, INC.: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 GLOBAL MEDICAL SOLUTIONS
             12.2.2 SHINE TECHNOLOGIES, LLC
             12.2.3 ISOTOPIA MOLECULAR IMAGING LTD.
             12.2.4 BWXT MEDICAL LTD.
             12.2.5 INSTITUTE OF ISOTOPES
             12.2.6 CHINA ISOTOPE & RADIATION CORPORATION
             12.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.
             12.2.8 CYCLOPHARM
             12.2.9 IRE ELIT
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 349)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Secondary Research

The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

Breakdown of Primary Interviews

Nuclear Medicine/Radiopharmaceuticals Market  Size, and Share

Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Report Metric

Details

Siemens Healthineers

Sr.Sales Manager

Curium

General Manager

Cardinal Health

Product Sales Specialist

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

Market Definition

Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

Key Stakeholders

  • Senior Management
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
  • To profile the key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

Available Customizations

MarketsandMarkets offers the following customizations for this market report:

  • Additional country-level analysis of the nuclear medicine market.
  • Profiling of additional market players (up to 3)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 3590
Published ON
May, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Nuclear Medicine Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback